Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Research shows that the strategies of the key layers have evolved to incorporate a higher market share. Thorough research is conducted to understand the demographics, psychographics, and medical needs of individuals affected by parathyroid disorders, including factors like age, gender, geographic location, and severity of the condition. A full spectrum of medications, as well as conservative and surgical treatments, is developed that targets various parathyroid diseases like hyperparathyroidism and hypoparathyroidism. Such comprehensive product portfolio is developed to promote patient well-being. Manufacturing companies stand out in the market through thorough testing, clinical trials, compliance to the standard laws, and they focus on the therapeutic and safety efficacy of products for parathyroid disorders which maintain the confidence of healthcare providers and patients. Affordable pricing and out-of-pocket payment strategy plus, the health insurance policies are taken into account when medical products for parathyroid disorders are offered so that the patients of any background can be guaranteed access to these products. The efficient channels of distributing the Remedy become the shared tools of hospitals, specialty pharmacies, patient referrals, and online platforms to guarantee the widespread presence of products targeting parathyroid problems. To the buyers, health care workers, and other partners, regulatory compliance and quality medical product development, manufacturing and marketing processes are the prerequisites to accountability and the establishment of a mutual platform for credibility and trust. The scale of geographical reach is broadened through new markets and territories which correspond to a high disease burden, and marketing strategies as well as product offerings are tuned to the health systems and local tendencies of the specific region. The brand is able to distinguish itself from the competitors but emphasizing and illuminating the singular features, benefits and the value of products dedicated for parathyroid disorders directing the brand as highly professional in its niche. The usage of data analysis and market insights for decision-making, creation of trend awareness, and marketing strategies improvement is done for larger impacts and get the maximum returns on investment. Sustainable business practices and initiatives that align with corporate social responsibility goals are developed, addressing environmental, social, and ethical considerations to enhance brand reputation and loyalty among stakeholders.
Parathyroid Disorders Market Highlights:
Parathyroid Disorders Market Scenario:
The Parathyroid Disorders Market Size was valued at USD 1.98 Billion in 2023. The Global Parathyroid Disorders industry is projected to grow from USD 2.15 Billion in 2024 to USD 3.86 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.69% during the forecast period (2024 - 2032). Parathyroid glands produce and secrete a parathyroid hormone which is involved in regulation of calcium and phosphorus metabolism. Hyperparathyroidism and Hypoparathyroidism are the two most common parathyroid disorders. The hyperparathyroidism is characterized by an excessive secretion of parathyroid hormone. The most common signs and symptoms of the disorder include kidney stones, bone and joint pain, fragile bones, weakness.
According to a study published in the Turkish Journal of Trauma and Emergency Surgery in 2016, it is found that hyperparathyroidism is the third most common clinical endocrine disorder with a prevalence between 0.1–1.0%, and an incidence of around 28 cases per 100,000 individuals. It also reported that the incidence rate is highest between 50 and above age group i.e. the condition is affecting 2% of the population aged 55 years or older.
Notably, rising prevalence of parathyroid disorders and growing geriatric population are the key factors driving the parathyroid disorders market.
Various other factors such as increasing incidences of parathyroid disorders, increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the parathyroid disorders market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.
Despite these drivers, there are some issues associated with parathyroid disorders market. Some of the challenges include less research and development funding, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.
Intended Audience:
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Medical Device Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Segmentation
The parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the parathyroid disorders market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.
On the basis of the diagnosis, the parathyroid disorders market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.
On the basis of the treatment, the parathyroid disorders market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.
On the basis of the end-user, the parathyroid disorders market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis:
The Americas dominate the parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.
The Asia Pacific region is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.
Key Players
Some of the key players in the parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
